John Valliant, PhD
Chief Executive Officer
Chief Regulatory Officer
Dr. John Valliant is the founder of CPDC. Dr. Valliant oversees the strategic directions of the scientific and commercial programs of the CPDC, to ensure the Centre’s long-term vision and sustainability.
John is currently Professor in the Department of Chemistry and Chemical Biology, at McMaster University. He is recognized internationally for his work in radiopharmaceutical chemistry. His current research focuses on developing novel radiolabeling methods and compound discovery strategies, in order to create clinically relevant imaging and therapeutic drug candidates. Thus far, John has published more than 100 peer review research papers and holds 16 patents in the area of radiochemistry and radiopharmaceuticals. He completed his PhD at McMaster University, followed by a post-doctoral fellowship under the joint supervision of professors Alun G. Jones (Harvard) and Alan Davison (MIT).
John was selected as one of ‘Canada’s Top 40 Under 40’ in 2009, a distinction that recognized his exceptional work to advance radiopharmaceutical technology and education, improve patient care, and generate economic growth, through his work at the CPDC and McMaster University. More recently he was a co-recipient of the Brockhouse Prize for Interdisciplinary Research in Science and Engineering (2015).
Dr. McCann has overall responsibility for the day-to-day operations of the CPDC. Prior to taking on this role, Dr. McCann was part of the commercial team leading manufacturing and development operations for the pharmacy and GMP manufacturing programs across all four CPDC sites. In the 7 years since joining the CPDC, Dr. McCann has led Quality Assurance and Process Development departments and teams responsible for the development and validation of 17 different imaging probe and radiotherapeutic programs, used in national and international clinical trials. Prior to joining CPDC, Dr. McCann was a Scientist in Pharmaceutical Development at GlaxoSmithKline, responsible for developing products across all stages of clinical development. Dr. McCann has a Ph.D. in biochemistry from McMaster University.
Dr. Goodbody oversees CPDC’s regulatory functions and clinical operations. Moreover, Anne is responsible for the quality and GMP compliance of the CPDC’s manufacturing network and has lead the Centre successfully through both Health Canada and FDA audits.
Anne has over 25 years of pharmaceutical research and development experience and is recognized as a Canadian leader and expert in radiopharmaceutical regulatory affairs. Prior to the CPDC, Anne was the VP of Drug Development at Vasogen Inc., an Ontario-based Drug Developer focused on therapies for inflammatory disorders. Anne also held senior roles including VP Development at Molecular Insight Pharmaceuticals,and Director of Biological Research at Resolution Pharmaceuticals.
Anne holds a PhD in biochemistry from the University of Cambridge (UK), and has published extensively, is a named inventor on 15 issued patents and has presented research at international conferences.
CPDC is governed by an independent Board of Directors. Board members represent all key sectors associated with the CPDC. The Board of Directors works with the CEO and CPDC executive team to shape the CPDC’s future direction and success.
Robert SutherlandChair, Centre for Probe Development and Commercialization
John ValliantFounder, Centre for Probe Development and Commercialization
Annick Van den AbbeeleChief, Department of Imaging, Dana-Farber Cancer Institute
Damian LambManaging Director, Genesys Capital
Mark LundieDirector Medical Affairs, Rare Diseases, Pfizer Canada Inc.
Alison Janidlo (Ex-Officio)Senior Program Manager, Networks of Centres of Excellence
Nick MarkettosAssistant Vice President, Research Partnerships, McMaster University
John ThornbackManaging Director, Apta Biosciences Pte Ltd
Hamilton, Ontario, October 3, 2018 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, today is announcing that its founder, Dr. John Valliant, has stepped down from his role as CEO to focus his time as the CEO of Fusion Pharmaceuticals. Dr. Valliant will
CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.
CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.
CPDC’s manufacturing facilities are approved by both Health Canada and the US FDA for the production of positron emitting radiopharmaceuticals.
Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.
During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.
CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.
CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.
Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.
Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.
ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.
Molecular PET imaging probes are used primarily to diagnose cancer, heart disease and neurological conditions.